A novel point mutation affecting Asn76 of dystrophin protein leads to dystrophinopathy by Koczok, Katalin et al.
Manuscript Details
Manuscript number NMD_2017_315
Title A novel point mutation affecting Asn76 of dystrophin protein leads to
dystrophinopathy
Article type Research paper
Abstract
Mutations in the DMD gene lead to Duchenne and Becker muscular dystrophy (DMD/BMD). Missense mutations are
rare cause of DMD/BMD. A six-month-old male patient presented with mild generalized muscle weakness, hypotonia,
and delayed motor development. Dystrophinopathy was suspected because of highly elevated serum creatine kinase
level (1497 U/L) and tiered DMD gene analysis was performed. Multiplex ligation-dependent probe amplification
(MLPA) assay showed deletion of exon 4, which could not be confirmed by another method. Sequencing of exon 4
revealed a novel de novo point mutation (c.227A>T, p.Asn76Ile) in the N-terminal actin binding domain (N-ABD) of
dystrophin protein. The false positive MLPA result was explained by the fact that the affected nucleotide lies directly at
the 3’ ligation site of the MLPA probe. Sequencing of the whole coding region of DMD gene proved c.227A>T to be the
sole variant being potentially pathogenic. According to in silico analyses the mutation was predicted to be highly
destabilizing on N-ABD structure possibly leading to protein malfunction. Muscle biopsy was performed and dystrophin
immunohistochemistry results were suggestive of BMD. Our results highlight the importance of confirmatory testing of
single-exon deletions detected by MLPA and we describe a novel, destabilizing missense mutation in the DMD gene.
Keywords Duchenne/Becker muscular dystrophy, MLPA, dystrophin, dystrophinopathy
Corresponding Author Istvan Balogh
Order of Authors Katalin Koczok, Gabriella Merő, Gabriella P. Szabó, László Madar, Éva
Gombos, Éva Ajzner, János András Mótyán, Tibor Hortobágyi, Istvan Balogh
Suggested reviewers Joachim Weis, Martin Lammens, Hans H. Goebel, Mária Judit Molnár, Rahul
Phadke, rita barresi
Submission Files Included in this PDF
File Name [File Type]
cover letter.doc [Cover Letter]
NMD_submission_checklist.docx [Checklist]
Highlights.docx [Highlights]
Asn76_manuscript_NeuromuscDis_final.doc [Manuscript File]
Figure3.tif [Figure]
Figure4.tif [Figure]
Figure5.tif [Figure]
Table1.doc [Table]
Figure1.xlsx [Table]
Figure2.xlsx [Table]
Statement.pdf [Author Agreement]
To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE
Homepage, then click 'Download zip file'.
Prof. Dr. Victor Dubowitz
Editor-in-Chief
Neuromuscular Disorders
Dubowitz Neuromuscular Center, London
Dear Professor Dubowitz,
Enclosed please, find our manuscript, entitled “A novel point mutation affecting 
Asn76 of dystrophin protein leads to dystrophinopathy” which we would like to 
publish in Neuromuscular Disorders. 
In the paper we present a comprehensive analysis of a very young patient with 
dystrophinopathy. Using different methods, including MLPA, next generation and 
Sanger sequencing we show the presence of a novel point mutation (c.227A>T, 
p.Asn76Ile) that is located in a critical part of the protein involved in actin binding. 
Using in silico methods we show that the mutation might have destabilizing effect 
which fact is supported by immunohistochemistry analysis.
We believe that the complexity of the presented case and the use of state-of-the-art 
methodology (i.e. very young age of the patient, false-positive MLPA analysis, 
identification of a novel missense mutation, next-generation sequencing of the entire 
coding region of the gene) might be interesting for a broader audience.
The detected novel mutation (LRG_199t1: c.227A>T, LRG_199p1: p.Asn76Ile) has 
been submitted to the LOVD database 
(https://databases.lovd.nl/shared/variants/0000171133).
We confirm that 
- all listed authors have actively participated in the study,
- all authors have seen and approved the manuscript,
- the study complies with the current ethical considerations,
- the manuscript reports previously unpublished work that will not be submitted to 
any other journal whilst it is under consideration by Neuromuscular Disorders,
- the authors have no conflict of interest.
Debrecen, 2017. 06. 27
Thank you for your consideration.
Yours sincerely,
Istvan Balogh PhD
Department of Laboratory Medicine, Division of Clinical Genetics
University of Debrecen
4032 Debrecen, Nagyerdei krt. 98., Hungary.
Tel.: (36) 52-340006; Fax: (36) 52-417631
e-mail: balogh@med.unideb.hu
SUBMISSION CHECKLIST for Neuromuscular Disorders
Please ensure that your paper conforms to the following guidelines. Once you have completed the 
checks, please upload this file as a separate document using the file type “Checklist”.
√ Title: No abbreviations are to appear in the title
√ Authors' names
√ Authors' affiliations/addresses
√ Address (including fax number and e-mail 
address) of the corresponding author
√  Abstract:
 max. 200 words (150 for Case Reports) 
 No abbreviations to appear in the abstract
 Continuous text with no sub-headings
√  Pages:  numbered
√ Keywords
√ Highlights: 3-5 bullet points (each to be no 
more than 85 characters including spaces)
√ Font size 12pt
√ Single-column printout 
√ Double-spaced text 
√ Language: 
 Spelling checked
 Grammar checked
√ Figures: 
Acceptable line quality and must fit on a 
portrait page
 Uploaded as separate files not embedded in 
the text
 Colour figures must clearly marked as being 
intended for colour reproduction
√ Consent for recognisable figures provided (if 
applicable) and uploaded with the manuscript files
√ Figure and Table legends: Separate list 
provided 
√ Tables: 
 Should be in portrait format, but if landscape 
they must fit across a portrait page
 Uploaded as separate files and not embedded 
in the text
√ References: For six or more authors, please list 
the first six names followed by “et al.”
√  Author Agreement: 
It is the corresponding author’s responsibility to 
ensure all co-authors have read and agreed the 
contents of the paper (on initial submission and on 
any revisions or subsequent resubmissions). Please 
prepare a statement confirming that all authors have 
agreed the contents of the submission. Please 
include the title and date, and signature. The 
corresponding author may sign on behalf of all co-
authors.
A novel point mutation affecting Asn76 of dystrophin protein leads to dystrophinopathy
Katalin Koczoka, Gabriella Merőb, Gabriella P. Szabóc, László Madara, Éva Gombosa, Éva 
Ajznerd, János András Mótyáne, Tibor Hortobágyif,g, István Balogha.
aDivision of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, 
University of Debrecen, Debrecen, Hungary; bDepartment of Pediatrics, Jósa András Teaching 
Hospital, Nyíregyháza, Hungary; cDepartment of Pediatrics, Faculty of Medicine, University 
of Debrecen, Debrecen, Hungary; dCentral Laboratory, Jósa András Teaching Hospital, 
Nyíregyháza, Hungary; eDepartment of Biochemistry and Molecular Biology, Faculty of 
Medicine, University of Debrecen, Debrecen, Hungary; fDivision of Neuropathology, 
Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 
gInstitute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK. 
Highlights
1. Missense mutations are rare cause of Duchenne/Becker muscular dystrophy and the 
major fraction of them occurs in the N-ABD of dystrophin protein.
2. Our results highlight the importance of confirmatory testing of single-exon deletions 
detected by MLPA.
3. To predict the severity of the phenotype may be challenging at very young age in the 
case of a novel missense mutation in the DMD gene.
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2Abstract
Mutations in the DMD gene lead to Duchenne and Becker muscular dystrophy (DMD/BMD). 
Missense mutations are rare cause of DMD/BMD. A six-month-old male patient presented 
with mild generalized muscle weakness, hypotonia, and delayed motor development. 
Dystrophinopathy was suspected because of highly elevated serum creatine kinase level (1497 
U/L) and tiered DMD gene analysis was performed. Multiplex ligation-dependent probe 
amplification (MLPA) assay showed deletion of exon 4, which could not be confirmed by 
another method. Sequencing of exon 4 revealed a novel de novo point mutation (c.227A>T, 
p.Asn76Ile) in the N-terminal actin binding domain (N-ABD) of dystrophin protein. The false 
positive MLPA result was explained by the fact that the affected nucleotide lies directly at the 
3’ ligation site of the MLPA probe. Sequencing of the whole coding region of DMD gene 
proved c.227A>T to be the sole variant being potentially pathogenic. According to in silico 
analyses the mutation was predicted to be highly destabilizing on N-ABD structure possibly 
leading to protein malfunction. Muscle biopsy was performed and dystrophin 
immunohistochemistry results were suggestive of BMD. Our results highlight the importance 
of confirmatory testing of single-exon deletions detected by MLPA and we describe a novel, 
destabilizing missense mutation in the DMD gene. 
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311. Introduction
Mutations in the DMD gene (Xp21.2-p21.1) encoding the protein dystrophin lead to the X-
linked allelic disorders Duchenne (DMD, MIM 310200) and Becker muscular dystrophy 
(BMD, MIM 300376), both characterized by progressive muscle wasting [1, 2]. DMD is the 
more severe form caused by mutations that result in nearly complete absence of dystrophin 
protein [3, 4]. BMD is the milder variant characterized by remarkable variability in 
presentation and progression of symptoms and associated with abnormal but partially 
functional dystrophin protein [5, 6]. Dystrophin is associated with the sarcolemma and 
interacts with integral membrane proteins assembled in the dystrophin-glycoprotein complex 
forming a link between the extracellular matrix and the cytoskeletal actin. Dystrophin’s main 
role is the stabilization of sarcolemma and the protection of muscle fibers from contraction-
induced damage [7]. Several isoforms of the protein are generated through different 
promoters and alternative splicing events. The full-length messenger RNA is predominantly 
expressed in skeletal and cardiac muscle and, to a lesser extent, in the brain [8]. The full-
length human dystrophin protein transcribed from the muscle promoter consists of 3685 
amino acids (molecular weight of 427 kDa) [1] and is predicted to fold into four structural 
domains: the N-terminal actin-binding domain (N-ABD or ABD1), a central rod domain 
(containing a second ABD, ABD2), a cysteine-rich domain and a C-terminal domain [9].
Clinical diagnosis of DMD/BMD based on elevated serum creatine kinase (CK) and/or 
muscle biopsy can be confirmed by molecular genetic testing of the DMD gene. The first tier 
1 Abbreviations: DMD, dystrophin gene; DMD, Duchenne muscular dystrophy; BMD, 
Becker muscular dystrophy; N-ABD, N-terminal actin binding domain; CK, creatine kinase; 
MLPA, multiplex ligation-dependent probe amplification; dbSNP, single nucleotide 
polymorphism database; MAF, minor allele frequency; ABS, actin binding site; ExAC, 
Exome Aggregation Consortium.
4genetic analysis is screening for deletions/duplications, which account for about 75-85% of 
genetic alterations in DMD/BMD patients [10, 11]. If no deletion or duplication is found, 
sequencing of the DMD gene as a second tier test can be offered [12]. The great majority of 
point mutations in the DMD gene so far identified are nonsense mutations, small frameshift 
deletions/insertions and splice-site mutations [8], missense mutations are rare cause of 
DMD/BMD. 
The DMD gene is one of the largest human genes spanning more than 2.5 million base pairs 
and consists of 79 exons [8]. The high mutation rate of the gene has been claimed to be the 
consequence of very large introns [13], in one of three patients the disease is the result of a de 
novo mutation [14]. Germline mosaicism is a significant contributing factor to introduce 
DMD gene mutations [15] and has to be taken into account when considering recurrence risk 
[16].
Structural elements that are responsible for the function of dystrophin (i.e. maintaining the 
link between actin and the extracellular matrix) are well characterized. An antiparallel dimer 
is formed by the N-ABDs of two dystrophin molecules, which can be seen in the crystal 
structure on human dystrophin protein [17] (Figure 5A). The N-ABD of human dystrophin is 
mainly helical and contains two calponin homology (CH) domains. Its CH1 and CH2 
subdomains are connected by a helical linker region (helix I) (Figure 5A). CH2 subdomain 
contains major (A, C, E, and G) and short (B, D, and F) helices. Overall fold of CH1 closely 
resembles that of CH2 but lacks the short B and D helices, which are substituted by loop 
regions in this subdomain (Figure 5A). Three actin-binding sites are responsible for 
interactions with actin molecules. The ABS1 (K18-A27) is located in helix A while the ABS2 
(N88-L116) mainly in F and G helices of CH1 subdomain. The ABS3 site (L131-S147) is 
located in helix A of CH2 subdomain. 
Here we report the detection of a novel missense mutation located in the N-ABD of 
5dystrophin protein affecting Asn76 residue. Interpretation of this novel genetic finding is 
given in the context of clinical picture, muscle biopsy analysis, and in silico analysis of 
protein structure.
2. Patients and methods
2.1 Case history
A six-month old male patient was sent for neurologic examination because of mild 
generalized muscle weakness, hypotonia, and delayed motor development. Perinatal 
anamnesis, mental development, and sensation were found to be normal normal. As in spite of 
sensory-motor training no improvement of symptoms was observed, a neuromuscular disease 
was suspected. Electromyography showed myopathic features (data not shown). Laboratory 
investigation at 1-year-old age showed markedly elevated serum creatine kinase (1497 U/L, 
reference range: 24-195 U/L) prompting the consideration of dystrophinopathy and DMD 
gene analysis was requested at age of 14 months. There was no family history of DMD/BMD. 
Follow-up physical examination revealed difficulties in sitting up from lying, scapula alata, 
decreased muscle bulk on upper extremities, and chest in addition to mild calf hypertrophy at 
the age of 4 years. Changes in serum creatine kinase values during follow-up time are shown 
in Figure 1.
2.2 Molecular genetic analysis
2.2.1 DNA isolation
Genomic DNA was extracted from peripheral blood leukocytes using the QIAamp DNA 
Blood Mini Kit (Qiagen, Hilden, Germany).
62.2.2 Deletion/duplication analysis of DMD gene
Multiplex ligation-dependent probe amplification (MLPA) analysis for the detection of 
deletions/duplications in the DMD gene was performed using the SALSA MLPA probe mixes 
P034-B2 DMD and P035-B1 DMD (MRC-Holland, Amsterdam, the Netherlands). Data were 
analyzed according to the manufacturer’s instructions. Briefly, relative peak heights were 
generated after intra- and inter-sample normalization using sex-matched control samples. 
Deletion of the probe’s recognition sequence leads to complete absence of the corresponding 
probe amplification product in males.
2.2.3 Sanger DNA sequencing of exon 4 of DMD gene 
After PCR amplification of the coding sequence and adjacent intronic regions of exon 4 of 
DMD gene bidirectional Sanger DNA sequencing was performed using amplification primers 
from the Chamberlain set [18] and the Big Dye Terminator v3.1 Cycle Sequencing kit 
according to the manufacturer’s instructions. Samples were run on ABI PRISM 310 Genetic 
Analyzer and data were analyzed using the Sequencing Analysis Software (Applied 
Biosystems, Foster City, CA, USA). 
2.2.4 Sequencing of the entire coding region of DMD gene 
Sequencing of DMD gene was performed by bidirectional pyrosequencing on GS Junior 
system using the DMD MASTR assay (Multiplicom, Niel, Belgium). Data were analyzed 
with the GS Amplicon Variant Analyzer software (Roche 454 Life Sciences, Branford, CT, 
USA).
2.3 Muscle histology, dystrophin immunohistochemistry
7The muscle biopsy specimen measuring 0,5x0.4x0,8 cm from left quadriceps muscle was 
divided into three equal parts and i) snap frozen in isopentane for histology and 
immunohistochemistry; ii) fixed in 4% phosphate-buffered paraformaldehyde (pH 7.4) for 
histology; iii) fixed in 3% phosphate-buffered glutaraldehyde (pH 7.4) to ensure tissue was 
available for electronmicroscopy if required (which was not the case here, because light 
microscopic and genetic analysis were sufficient to provide the diagnosis). Frozen sections of 
7 micrometer thickness were cut for detailed muscle biopsy analysis. Staining, enzyme- and 
immunohistochemistry was performed according to diagnostic guidelines and standard 
protocols. In brief, sections were stained by haematoxylin and eosin (H&E) for general 
neuropathological analysis, by periodic-acid Schiff reaction (PAS) with and without diastase 
treatment for assessment of glycogen, with Sudan-black for lipids, with Gömöri’s trichrome 
for assessment of mitochondrial pathology, fibrosis, and inclusions. Fiber type analysis was 
performed following ATPase detection by enzyme histochemistry at pH 4.2, 4.6, and 9.4, 
respectively. Mitochondrial function and myofibrillary architecture was assessed following 
succinate dehydrogenase (SDH), nicotinamide adenine dinucleotide dehydrogenase (NADH), 
and cytochrome oxidase (COX) enzyme histochemistry. Immunohistochemistry was 
performed by using antibodies against sarcolemmal and sarcolemma-associated proteins: 
dystrophin targeting epitopes 1, 2, and 3, corresponding to central/core, C-terminal and N-
terminal regions, respectively, (Novocastra, Newcastle, UK, distributed by Biomarker, 
Gödöllő, Hungary; primary antibody dilution was 1:20 in all cases), sarcoglycan alpha, beta, 
gamma, and delta (Novocastra, 1:50, 1:100, 1:100, and 1:50, respectively); merosin 
(Novocastra, 1:100) and spectrin (Novocastra, 1:100). Primary antibodies were incubated on 
slides for 1 hour at room temperature.
2.4 In silico analyses
8Crystal structures of the ABDs of dystrophin (PDB ID: 1DXX) [17], utrophin (PDB ID: 
1QAG) [19], α-actinin 3 (PDB ID: 1WKU) [20], and fimbrin (PDB ID: 1AOA) [21] proteins 
were downloaded from Protein Data Bank database, while other protein information from 
UniProt database for dystrophin (UniProt ID: P11532), utrophin (UniProt ID: P46939), α-
actinin 3 (UniProt ID: Q08043), and fimbrin (UniProt ID: P13797). Structural figures were 
prepared by PyMOL Molecular Graphics System (Version 1.3 Schrödinger, LLC). Structure-
based sequence alignment was performed by using SALIGN web server [22]. Secondary 
structure predictions were performed by JPred4 server [23]. FoldX algorithm [24] and SDM 
web server [25] were used to calculate protein stability changes (ΔΔG, kcal/mol) upon point 
mutations using crystal structure of dystrophin ABD. Aggregation properties were predicted 
based on the structure of chain A of N-ADB by Aggrescan3D server using dynamic mode of 
prediction [26].
3. Results
3.1 Molecular genetic testing of DMD gene
Deletion/duplication testing of DMD gene by MLPA showed complete absence of the 
amplification product of probes hybridizing to exon 4 (Figure 2). PCR amplification of exon 
4, however, did not confirm the deletion. Sanger sequencing of exon 4 revealed a novel point 
mutation (LRG_199t1: c.227A>T, LRG_199p1: p.Asn76Ile; submitted to LOVD database 
(https://databases.lovd.nl/shared/variants/0000171133) leading to the change of Asn residue 
to Ile at the 76th position (Figure 3). The mutation proved to be de novo being not detectable 
in the mother genomic DNA (Figure 3). In order to exclude the possibility of another 
potentially pathogenic mutation in the DMD gene, the whole coding region of the gene was 
sequenced. Data analysis of promoter, exonic regions, and +/-5 nucleotides from the 
9exon/intron boundaries revealed three hemizygous variants. Beside the unreported missense 
mutation c.227A>T, previously detected by Sanger sequencing, two other variants were found 
(both to be found in the Single Nucleotide Polymorphism Database (dbSNP) with >5% minor 
allele frequency (MAF), Table 1). 
3.2 Muscle histology, dystrophin immunohistochemistry 
In transverse sections the variation in fibre size was moderately increased due to the presence 
of scattered fibres which were either smaller than normal (atrophic) or moderately enlarged 
(hypertrophic). Occasional hypercontracted fibres were also detectable (a feature which is not 
pathological in biopsy specimens). The nuclei were predominantly in their physiological 
subsarcolemmal position. However, internalised nuclei were also noted in some parts of the 
biopsy affecting up to 8% of all fibres. The overall internal nucleation was not in the 
pathological range. There was no increase of the endomysial connective tissue. The blood 
vessels were normal. In small groups basophilic degenerative or regenerative fibres were 
detectable; such groups had approximately 30 fibres. Similar basophilic fibres were seen 
scattered amongst normal-appearing, mildly hypertrophic or atrophic fibres. The proportion of 
these fibres was not more than 1:50 (2%). Although these atrophic fibres were sometimes in 
perifascicular distribution, this was not characteristic feature in the biopsy and the findings 
were not those of dermatomyositis (where perifascicular atrophy is a prominent feature). 
There was no significant inflammatory cell infiltrate, although there were occasional 
mononuclear inflammatory cells, predominantly in areas rich in basophilic fibres. At the 
periphery of the biopsy occasional necrotic fibres were noted. No inclusions and no genuine 
vacuolisation was noted (there was mild freezing artefact in forms of small vacuoles, though) 
(Figure 4A). With special stains (PAS, PAS-diastase, Sudan-black) there was no evidence of 
abnormal glycogen or lipid accumulation. With ATPase reactions at 3 different pH (pH 4.2, 
10
4.6, and 9.4) there was mild fibre type 1 predominance (which is not pathological in this 
muscle). The variation in fibre size affected the different fibre types equally. There was no 
evidence of fibre splitting. Cytochrome oxidase (COX) revealed occasional pale fibres and no 
COX negative fibres. There was no evidence of protein aggregates, subsarcolemmal increased 
staining intensity with this stain. With Gömöri’s trichrome no features of mitochondrial 
myopathy (such as ragged red fibres) were noted and there were no inclusions (such as 
nemaline rods). With the NADH reaction the disruption of the myofibrillary architecture was 
noted in the degenerative and necrotic fibres; occasional dark fibres were also noted. 
Dystrophin expression was analysed by means of immunohistochemistry using three 
antibodies targeting the centre (core), C-terminal and N-terminal region of the protein, 
designated as anti-dystrophin 1, 2, and 3 antibody, respectively. With antibody 1 there was 
variably intensity of sarcolemmal staining, segmentally severely reduced or lost. With 
antibody 2 there was intense, linear sarcolemmal expression consistent with normal staining 
pattern. With antibody 3 the majority of the fibres were negative, with segmental sarcolemmal 
expression in less than 5% of the fibres (Figure 4B, C, D respectively). The spectrin 
immunohistochemistry revealed normal, linear sarcolemmal expression. The α, β, γ, and d 
sarcoglycan showed linear sarcolemmal expression of moderate to high intensity, in 
occasional fibres with segmental decrease of expression. Merosin showed strong, linear, 
sarcolemmal expression (Figure 4F). All immunohistochemical reactions were performed 
parallel with the respective positive and negative controls (Figure 4E). The dystrophin 
immunohistochemistry has been repeated to confirm findings. 
3.3 Predicting the effects of Asn76Ile mutation
3.3.1 Asn76 residue of human dystrophin
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Structure of the N-ABD of human dystrophin was analyzed to explore the possible role of 
Asn76 residue in domain stabilization. 
Based on the crystal structure, the Asn76 residue is located within the N-ABD, in helix E of 
CH1 subdomain (Figure 5A). According to published data, Asn76 does not constitute a part of 
any actin binding site (ABS) and is not involved directly in actin binding [17]. Side chain of 
Asn76 is not exposed to the surface of CH1 subdomain, rather it is buried between C and E 
helices and loop D. Side chain atoms of Asn76 are within hydrogen bond distance with main 
chain atoms of Asp46 and Glu65 residues in the crystal structure of N-ADB (Asn76.ND2-
Asp46.O and Asn76.OD1-Glu65.N, respectively). These H-bonds may provide stabilizing 
interactions within the CH1 subdomain, making contact between helix E (Asn76), loop B 
(next to the N-terminal end of helix C) (Asp46), and loop D (Glu65) (Figure 5A).
3.3.2 Structure-based alignment of CH1 subdomain-containing proteins
Sequence alignment of human dystrophin, utrophin, α-actinin 3, and fimbrin protein N-ABDs 
showed high conservation of Asn76 residue (dystrophin numbering) (Figure 5C), in good 
agreement with the previously published analyses [17, 27, 28]. Conservation of Asp46 and 
Glu65 residues interacting with Asn76 was also investigated. The Asp residue (Asp46 
according to dystrophin numbering) was found to be not fully conserved in the case of aligned 
CH1 subdomain-containing human protein sequences (Figure 5C), while 1 and 4 isoforms of 
α-actinin contain Asp residue, Asn can be found in this position in isoform 2 and 3 (data not 
shown). Residues corresponding to Glu65 of human dystrophin show the conservation of side 
chains having strongly similar properties (Asn, Asp, or Glu) in this position (Figure 5C).
3.3.3 Predicted effects of Asn76Ile mutation
12
Secondary structure prediction was performed using the sequence of p.Asn76Ile mutant N-
ABD and showed no disruption of helix E, the mutant protein was predicted to maintain the 
overall secondary structural organization of the N-ABD of wild type.
Structure of the mutant human dystrophin protein (generated by FoldX) showed the loss of 
the conserved H-bonds of Asn76 with the neighboring Asp46 and Glu65 residues, due to the 
substitution of a polar Asn residue to a hydrophobic Ile. The mutation was predicted to be 
highly destabilizing (∆∆G > 3 kcal/mol) implying its possible association with protein 
malfunction. 
The impact of p.Asn76Ile mutation on dystrophin aggregation propensity/solubility was also 
predicted. The analysis showed that both wild type (Asn76) and mutated (Ile76) residues are 
buried and are not part of aggregation-prone regions in CH1 subdomain.
 4. Discussion
Here we report a case of a 14-months old male patient with markedly elevated creatine kinase 
level, mild hypotonia, and gross motor delay suggesting BMD/DMD. For the molecular 
genetic confirmation of dystrophinopathy a tiered genetic approach of the DMD gene was 
performed starting with MLPA analysis showing deletion of exon 4. Single exon deletions 
detected by MLPA always need to be confirmed by another method [29] and successful PCR 
amplification of exon 4 proved that our MLPA result must have been false positive. Sanger 
sequencing of exon 4 showed A-to-T transversion at the 227th nucleotide position lying 
directly at the 3’ ligation site of the MLPA probe most likely leading to unsuccessful ligation 
and thus amplification. Sequencing of the entire coding region of DMD gene revealed no 
other potentially pathogenic variant except for the novel point mutation c.227A>T, previously 
detected by Sanger sequencing. 
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The c.227A>T variant was classified as likely pathogenic according to recently published 
criteria [30] upon the following: i) strong evidence is that the detected variant is de novo (the 
mutation was absent in the mother in a patient with disease and no family history), ii) 
moderate evidence is that it is absent from individuals in the 1000 Genomes Project and 
Exome Aggregation Consortium (ExAC), iii) supporting evidences are that the affected amino 
acid residue is evolutionary conserved between species and the patient’s phenotype is highly 
specific for a disease with single genetic etiology. Markedly elevated CK levels and the 
clinical picture suggested dystrophinopathy. In order to further support pathogenicity of the 
detected variant and discriminate between BMD and DMD, muscle biopsy was performed.
The light microscopic examination revealed mild myopathic changes with regenerative 
activity. The expression pattern of dystrophin was pathological, with severely reduced and 
segmentally absent staining with one of the anti-dystrophin antibodies (dystrophin-1, 
targeting the core region of the protein), and with absent or severally reduced staining with 
dystrophin 3 antibody (targeting the N-terminal end of the protein). These findings are 
consistent with the DMD gene mutation revealed by the mutation analysis.
Although missense mutations are rarely detected in DMD/BMD patients, a major fraction of 
them occurs in the N-ABD of the dystrophin protein [31, 32].
Studies on human dystrophin are restrained by the problems of high-yield expression and 
purification of the full-length protein, therefore, studies mainly on the individual ABDs are 
published [33], and crystal structures of only the N-ABD, a WW- and EF-hand motif-
containing fragment of the cysteine-rich domain, and the first spectrin repeat have been 
solved till now (last accession of PDB database: 12th June 2017). We also studied the 
dystrophin at the level of the N-ABD and used in silico methods to predict the effects of the 
detected point mutation on protein structure and stability, using the sequence and crystal 
structure of human dystrophin N-ABD. In addition, the predicted effects of p.Asn76Ile 
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mutation were compared to previously studied effects of p.Lys18Asn and p.Leu54Arg 
mutations [28, 33], being associated with DMD.
Not only sequence alignment (Figure 5C) but structural comparison of some CH1 subdomain-
containing proteins (Figure 5B) also showed the conservation of Asn residue in this position 
(Asn76 according to dystrophin numbering). Similarly to the high conservation of Lys18 and 
the interacting Asn39 and Phe41 residues [33], our alignments also showed that the 
interactions of Asn76 with the surrounding Asp46 and Glu65 residues are conserved, 
suggesting the structural importance of these bonds in domain stabilization. 
Substitution of Asn76 residue to Ile showed no impact on the secondary structure of helix E, 
and based on our predictions the p.Lys18Asn and p.Leu54Arg single mutants also share the 
secondary structure with the wild type ADB domain. This is in good agreement with the 
results of circular dichroism measurements, which indicated no alteration of global secondary 
structure of the ABD upon p.Lys18Asn mutation [33]. Extensive molecular dynamics 
simulations showed decrease or loss of helix I helicity in the case of p.Leu54Arg and 
p.Lys18Asn mutants, respectively, implying local conformational changes and long distance 
effects for the p.Lys18Asn and p.Leu54Arg mutations [28], but simple secondary structure 
prediction methods are not effective enough to predict the structural changes of the regions 
located distant from the site of p.Asn76Ile mutation. However, structural changes upon point 
mutations could be explored by experimental techniques or by extensive molecular dynamical 
calculations, these examinations were out of the scope and extent of this study.
Stability analysis showed highly destabilizing nature of p.Asn76Ile non-synonymous 
mutation. The p.Leu54Arg mutation was also predicted to have highly destabilizing nature 
(∆∆G > 5 kcal/mol), in good agreement with the previously considered effect of this mutation 
which affects the hydrophobic core of CH1 subdomain [31].
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As p.Asn76Ile mutation has no effect on the secondary structure of ABD based on our 
predictions, it probably causes local conformational changes due to the disruption of 
stabilizing interactions within the CH1 subdomain. The mutation may alter the flexibility of 
loop B (due to the loss of Asn76-Asp46 H-bond between helix E and loop B) and spatial 
positions of loop D residues (due to the loss of Asn76-Glu65 H-bond between helix E and 
loop D), as well. Conformation of helix C could be also affected by the p.Asn76Ile mutation, 
because there is no direct hydrogen bond between helix E and helix C, only Asp46 located 
next to the N-terminal end of helix C interacts with Asn76 residue. Lys18 residue located in 
helix A of CH1 subdomain was also reported to stabilize the conformation of a turn in 
neighboring loop B, and its mutation disrupts the interactions between the residues of helix A 
(Lys18) and loop B (Asn39 and Phe41) leading to increased flexibility of loop B [33]. 
Although neither the wild type nor the p.Asn76Ile mutant ABD showed increased aggregation 
propensity of CH1 subdomain, interestingly, the most aggregation-prone human dystrophin 
models showed the highest root-mean-square deviation values for the residues of helix I and 
CH2 subdomain compared to the wild type protein. These results correspond to the changes 
observed previously by molecular dynamics simulations of Chakravarty and its coworkers, 
who found that p.Lys18Asn and p.Leu54Arg mutations compromise the helicity of helix I 
region and higher root-mean-square fluctuation values were observed for CH2 subdomain 
compared to CH1 [28]. This also indicates long distance effects for p.Asn76Ile mutation. 
5. Conclusion
To predict the severity of the phenotype is challenging due to two facts. First, the detected 
likely causative genetic alteration is an unreported missense mutation. Second, the very early 
phenotypic observation of the patient resulted in an early genetic and pathological testing, 
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before the occurrence of the typical DMD/BMD symptoms. It is not possible to discriminate 
between BMD and DMD based on clinical features as the patient is only 4-year-old yet. In 
silico analyses of the protein structure supports the mutation pathogenicity but cannot provide 
information about disease severity. In this case, based on dystrophin immunohistochemistry 
results, we think that p.Asn76Ile mutation most likely leads to BMD, which diagnosis clearly 
needs to be re-evaluated over time on a clinical basis. As the mutation is a de novo point 
mutation for counselling purposes 2% recurrence risk has to be taken into consideration [16]. 
From the molecular genetic analysis point of view, our results highlight the importance of 
confirmatory testing of single-exon deletion MLPA results.
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Figure 1. Serum creatine kinase activity during follow-up time. Changes in the serum 
creatine kinase activity showed an increasing tendency over time. The grey zone indicates the 
reference range (24-195 U/L). CK, creatine kinase.
Figure 2. MLPA analysis of the DMD gene. Relative peak height values of probes 
hybridizing to exon 4 and two neighboring exons are shown. There was no amplification 
product of exon 4 in the patient DNA (light grey) sample (dark grey - normal control (male) 
DNA sample).
Figure 3. Sanger DNA sequencing of the DMD gene. A novel missense mutation (arrow, 
LRG_199t1: c.227A>T, LRG_199p1: p.Asn76Ile) was detected in the patient (upper panel) in 
exon 4. It proved to be de novo as it was absent in his mother (lower panel).
Figure 4. Muscle biopsy. (A) Increased variation in fiber size, internalized nuclei, few 
necrotic and basophilic regenerative fibers are seen. (B) There is reduced labelling with 
antibody recognizing the Dystrophin-1 epitope with segmental loss in numerous fibres. (C) 
Dystrophin-2 epitope shows normal linear sarcolemmal expression. (D) Dystrophin-3 epitope 
expression is noted only in occasional fibers with segmental distribution. (E) The negative 
control with omission of the primary antibody does not show staining. (F) The merosin 
expression is normal, with strong, linear staining of the sarcolemma.
Figure 5. Structure and sequence of human dystrophin, utrophin, α-actinin 3, and fimbrin 
proteins. A) Cartoon representation of ABD of human dystrophin. Left panel: antiparallel 
dimer formed by N-terminal ABDs. Middle panel: structure of the CH1 subdomain, the helix 
and loop numbering is indicated. Right panel: stick representation of Asn76, Glu65, and 
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Asp46 residues within CH1 subdomain; distances (Å) between the interacting atoms are 
indicated. B) Interactions of the conserved Asn residues in human utrophin, α-actinin 3, and 
fimbrin proteins. Regions corresponding to helix C, loop D, and helix E of human dystrophin 
are shown. Interacting residues are indicated by stick representation, residue names and 
distances (Å) are also indicated. C) Structure-based sequence alignment of actin-binding 
domains. Sequence numbering and secondary structural organization of human dystrophin is 
indicated above the aligned sequences. Helices and loops are labelled; Asp46, Glu65, and 
Asn76 residues (dystrophin numbering) are highlighted by green color. 



Table 1. Detected variants in the DMD gene by pyrosequencing.
Localization Genotype (hemizygous)a Effect on proteinb dbSNP IDc MAFd
exon 4 c.227A>T p.Asn76Ile - -
exon 37 c.5234G>A p.Arg1745His rs1801187 0.47
exon 59 c.8810A>G p.Gln2937Arg rs1800280 0.12
Sequencing of the DMD gene revealed three hemizygous variants, two of them with a >5% 
MAF and an unreported missense mutation, c.227A>T. cdbSNP ID, single nucleotide 
polymorphism database identification number; dMAF, minor allele frequency, 1000 Genomes 
Project. Reference sequences: aLRG_199t1 and bLRG_199p1.
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